See more : YU-WA Creation Holdings Co.,Ltd. (7615.T) Income Statement Analysis – Financial Results
Complete financial analysis of RadNet, Inc. (RDNT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of RadNet, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Texmaco Rail & Engineering Limited (TEXRAIL.BO) Income Statement Analysis – Financial Results
- Athene Holding Ltd. (ATH) Income Statement Analysis – Financial Results
- Walton Advanced Engineering, Inc. (8110.TW) Income Statement Analysis – Financial Results
- Orbit Technologies Ltd (ORBI.TA) Income Statement Analysis – Financial Results
- South32 Limited (SOUHY) Income Statement Analysis – Financial Results
RadNet, Inc. (RDNT)
About RadNet, Inc.
RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the diagnostic imaging industry, including picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of images in the field of mammography, as well as AI solutions for lung and prostate cancer. As of December 31, 2021, it owned and managed 347 centers in Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. The company was founded in 1981 and is headquartered in Los Angeles, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.62B | 1.43B | 1.32B | 1.07B | 1.15B | 975.15M | 922.19M | 884.54M | 809.63M | 717.57M | 702.99M | 647.15M | 619.80M | 548.54M | 524.37M | 502.12M | 425.47M | 161.01M | 145.57M | 137.28M | 140.26M | 139.28M | 111.84M | 87.96M | 72.30M | 58.82M | 67.02M | 56.54M | 45.34M |
| Cost of Revenue | 1.40B | 1.26B | 1.12B | 965.90M | 999.69M | 867.55M | 802.38M | 775.80M | 708.29M | 602.65M | 598.66M | 542.99M | 477.83M | 420.97M | 397.75M | 384.30M | 330.55M | 120.34M | 109.01M | 105.83M | 106.08M | 105.47M | 78.01M | 62.01M | 59.30M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 221.39M | 165.72M | 191.80M | 105.94M | 154.49M | 107.60M | 119.81M | 108.73M | 101.34M | 114.92M | 104.33M | 104.16M | 141.97M | 127.56M | 126.62M | 117.82M | 94.92M | 40.66M | 36.56M | 31.45M | 34.18M | 33.81M | 33.83M | 25.95M | 13.00M | 58.82M | 67.02M | 56.54M | 45.34M |
| Gross Profit Ratio | 13.69% | 11.59% | 14.58% | 9.88% | 13.39% | 11.03% | 12.99% | 12.29% | 12.52% | 16.01% | 14.84% | 16.10% | 22.91% | 23.26% | 24.15% | 23.46% | 22.31% | 25.26% | 25.12% | 22.91% | 24.37% | 24.27% | 30.25% | 29.50% | 17.98% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.82M | 2.88M | 745.00K | 1.24M | 806.00K | 2.74M | 0.00 | 838.00K | 731.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -2.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 0.00 | 123.06M | 0.00 | 0.00 | 0.00 | 0.00 | 1.82M | 2.88M | 745.00K | 1.24M | 806.00K | 736.00K | 1.39M | 838.00K | 731.00K | 30.83M | 27.47M | 7.63M | 5.63M | 3.91M | 4.94M | 7.18M | 4.02M | 2.58M | 3.10M | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 122.69M | 115.88M | 87.58M | 60.53M | 80.61M | 181.00K | 258.00K | 2.61M | 2.85M | 2.03M | -228.00K | 3.68M | 92.16M | 87.16M | 86.50M | 54.40M | 45.35M | 16.77M | 17.10M | 17.76M | 16.87M | 15.31M | 10.71M | 8.77M | 7.50M | 75.33M | 74.02M | 58.37M | 98.12M |
| Operating Expenses | 122.69M | 115.88M | 87.58M | 60.53M | 80.61M | 72.90M | 66.80M | 66.61M | 60.61M | 59.26M | 58.89M | 57.74M | 93.55M | 87.99M | 87.24M | 85.23M | 72.82M | 24.39M | 22.73M | 21.67M | 21.82M | 22.49M | 14.73M | 11.35M | 10.60M | 75.33M | 74.02M | 58.37M | 98.12M |
| Cost & Expenses | 1.52B | 1.38B | 1.21B | 1.03B | 1.08B | 940.45M | 869.17M | 842.41M | 768.90M | 661.91M | 657.55M | 600.73M | 571.38M | 508.97M | 484.99M | 469.53M | 403.37M | 144.74M | 131.74M | 127.50M | 127.90M | 127.97M | 92.74M | 73.37M | 69.90M | 75.33M | 74.02M | 58.37M | 98.12M |
| Interest Income | 0.00 | 11.22M | 27.16M | 48.41M | 48.04M | 39.54M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 139.64K | 295.17K | 258.39K | 295.61K |
| Interest Expense | 64.48M | 50.84M | 48.83M | 45.88M | 48.04M | 43.46M | 40.62M | 43.46M | 41.68M | 42.73M | 45.79M | 53.78M | 52.80M | 48.40M | 49.19M | 51.81M | 44.31M | 20.36M | 17.49M | 17.29M | 17.95M | 16.69M | 13.62M | 13.14M | 0.00 | 9.28M | 9.84M | 7.89M | 6.18M |
| Depreciation & Amortization | 189.49M | 184.72M | 170.66M | 154.71M | 147.45M | 72.90M | 66.80M | 66.61M | 60.61M | 59.26M | 58.89M | 57.74M | 57.48M | 54.00M | 53.80M | 53.55M | 45.28M | 16.39M | 16.94M | 17.76M | 16.94M | 15.31M | 10.71M | 8.77M | 7.50M | 8.64M | 8.78M | 6.04M | 8.63M |
| EBITDA | 292.79M | 278.53M | 278.37M | 199.74M | 225.16M | 107.60M | 119.81M | 108.73M | 116.94M | 114.92M | 104.33M | 108.51M | 105.90M | 81.14M | 85.38M | 86.84M | 67.52M | 32.66M | 30.94M | 29.02M | 29.30M | 25.20M | 28.65M | 23.37M | 9.90M | -7.87M | 1.78M | 4.21M | -44.15M |
| EBITDA Ratio | 18.11% | 17.00% | 20.13% | 19.40% | 19.86% | 16.27% | 14.49% | 13.69% | 13.97% | 17.27% | 15.69% | 16.66% | 17.09% | 17.06% | 17.77% | 17.29% | 15.63% | 22.31% | 20.89% | 21.14% | 20.73% | 18.96% | 23.35% | 26.67% | 16.46% | -6.83% | -19.41% | 5.53% | -98.28% |
| Operating Income | 98.70M | 46.36M | 82.55M | 53.23M | 69.88M | 30.89M | 50.05M | 38.48M | 39.12M | 53.31M | 43.60M | 45.23M | 50.66M | 38.44M | 38.86M | 32.59M | 21.17M | 16.27M | 13.84M | 9.78M | 12.36M | 11.32M | 19.10M | 14.60M | 2.40M | -16.51M | -7.67M | -1.83M | -52.78M |
| Operating Income Ratio | 6.11% | 3.24% | 6.28% | 4.97% | 6.05% | 3.17% | 5.43% | 4.35% | 4.83% | 7.43% | 6.20% | 6.99% | 8.17% | 7.01% | 7.41% | 6.49% | 4.97% | 10.11% | 9.50% | 7.12% | 8.81% | 8.12% | 17.08% | 16.59% | 3.32% | -28.07% | -11.44% | -3.24% | -116.40% |
| Total Other Income/Expenses | -59.89M | -3.39M | -23.68M | -36.54M | -40.21M | 7.64M | -23.67M | -26.04M | -24.47M | -49.65M | -37.72M | -40.85M | -47.72M | -58.77M | -49.05M | -51.66M | -40.30M | -23.16M | -16.54M | -18.92M | -5.37M | -15.06M | -9.27M | -96.58K | -2.00M | -3.85M | 7.67M | 1.08M | -5.48M |
| Income Before Tax | 38.81M | 42.97M | 58.88M | -854.00K | 29.67M | 38.53M | 26.39M | 12.44M | 14.65M | 3.65M | 5.89M | -2.10M | 2.94M | -20.34M | -10.19M | -19.07M | -18.13M | -6.89M | -3.14M | -9.34M | -5.36M | -5.17M | 9.18M | 14.50M | 400.00K | -20.36M | 7.11M | -754.87K | -58.26M |
| Income Before Tax Ratio | 2.40% | 3.00% | 4.48% | -0.08% | 2.57% | 3.95% | 2.86% | 1.41% | 1.81% | 0.51% | 0.84% | -0.32% | 0.47% | -3.71% | -1.94% | -3.80% | -4.26% | -4.28% | -2.15% | -6.80% | -3.82% | -3.71% | 8.21% | 16.48% | 0.55% | -34.61% | 10.62% | -1.34% | -128.48% |
| Income Tax Expense | 8.47M | 9.36M | 14.56M | 895.00K | 6.23M | 394.00K | 24.31M | 4.43M | 6.01M | 1.97M | 3.51M | -59.91M | 820.00K | 576.00K | 443.00K | 151.00K | 337.00K | 23.25M | 17.13M | 5.24M | -2.20K | 16.87M | -5.11M | 11.98M | 11.40M | 12.81M | -6.26M | 6.53M | 8.65M |
| Net Income | 3.04M | 33.61M | 44.32M | -1.75M | 23.44M | 32.24M | 53.00K | 7.23M | 7.71M | 1.38M | 2.12M | 64.52M | 7.23M | -12.85M | -2.27M | -12.84M | -18.13M | -6.89M | -3.14M | -14.58M | -2.27M | -5.55M | 14.50M | 2.61M | -9.00M | -29.32M | -748.10K | -8.36M | -61.43M |
| Net Income Ratio | 0.19% | 2.35% | 3.37% | -0.16% | 2.03% | 3.31% | 0.01% | 0.82% | 0.95% | 0.19% | 0.30% | 9.97% | 1.17% | -2.34% | -0.43% | -2.56% | -4.26% | -4.28% | -2.15% | -10.62% | -1.62% | -3.99% | 12.97% | 2.97% | -12.45% | -49.85% | -1.12% | -14.79% | -135.47% |
| EPS | 0.05 | 0.60 | 0.84 | -0.03 | 0.47 | 0.67 | 0.00 | 0.16 | 0.18 | 0.03 | 0.05 | 1.71 | 0.19 | -0.35 | -0.06 | -0.36 | -0.52 | -0.33 | -0.15 | -0.71 | -0.12 | -0.27 | 0.74 | 0.14 | -0.46 | -1.50 | -0.04 | -0.43 | -3.07 |
| EPS Diluted | 0.05 | 0.59 | 0.83 | -0.03 | 0.47 | 0.66 | 0.00 | 0.15 | 0.17 | 0.03 | 0.05 | 1.64 | 0.19 | -0.35 | -0.06 | -0.36 | -0.52 | -0.33 | -0.15 | -0.71 | -0.11 | -0.27 | 0.68 | 0.14 | -0.46 | -1.50 | -0.04 | -0.43 | -3.07 |
| Weighted Avg Shares Out | 63.58M | 56.29M | 52.50M | 50.89M | 49.67M | 48.11M | 46.88M | 46.24M | 43.81M | 41.07M | 39.14M | 37.75M | 37.37M | 36.85M | 36.05M | 35.72M | 34.59M | 21.01M | 20.60M | 20.46M | 18.89M | 20.44M | 19.98M | 19.50M | 19.49M | 19.53M | 19.43M | 19.59M | 20.02M |
| Weighted Avg Shares Out (Dil) | 64.66M | 57.32M | 53.42M | 50.89M | 50.24M | 48.68M | 47.40M | 46.66M | 45.17M | 43.15M | 39.81M | 39.24M | 38.79M | 36.85M | 36.05M | 35.72M | 34.59M | 21.01M | 20.60M | 20.46M | 20.54M | 20.44M | 22.09M | 19.92M | 19.49M | 19.53M | 19.43M | 19.59M | 20.02M |
Ketryx Announces DeepHealth Selected Its Software to Accelerate AI-Powered Health Informatics Innovation
CAMBRIDGE, Mass. , Dec. 4, 2024 /PRNewswire/ -- Ketryx announced today that DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly-owned subsidiary of RadNet, Inc. (Nasdaq: RDNT), has selected Ketryx to accelerate the delivery of AI-powered health informatics...
Hunting For Magnificent Growth Next Year? Check Out These 7 Stocks.
None of our picks is Nvidia or Amazon or Tesla. Investors may wish to widen the aperture to find the best stocks for outsize earnings growth.
RDNT Stock Up Post New Tie-Up to Boost Ultrasound Workflows With AI
RadNet's latest collaboration aims to create an AI-powered SmartTechnology to improve patient experience and operational efficiency in ultrasound.
RDNT Stock Up Following the New Tie-Up to Leverage Radiology AI
RadNet's latest collaboration aims to create an AI control system for image interpretation to ensure AI scalability, performance monitoring and safety.
RadNet, Inc. to Present at the BofA Securities 2024 Leveraged Finance Conference on December 3, 2024
LOS ANGELES, Dec. 02, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Mark Stolper, Executive Vice President...
RadNet's Wholly-Owned Subsidiary, DeepHealth, Launches New AI-powered Informatics and SmartTechnology™ Innovations at #RSNA2024
LOS ANGELES and SOMERVILLE, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) -- DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly-owned subsidiary of RadNet, Inc. (Nasdaq: RDNT), has launched new AI-powered solutions at RSNA 2024. These solutions enable...
Siemens Healthineers and RadNet's Wholly-Owned Subsidiary, DeepHealth, to Collaborate Around Elevating Ultrasound Workflows with AI-Powered SmartTechnology™
LOS ANGELES and SOMERVILLE, Mass., Dec. 01, 2024 (GLOBE NEWSWIRE) -- Siemens Healthineers and DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly-owned subsidiary of RadNet, Inc. (Nasdaq: RDNT), today announced a strategic collaboration aimed at transforming...
Maverick Medical AI Announces Completion of The Implementation of Its Real-Time Autonomous Medical Coding Solution at RadNet
WILMINGTON, Del.--(BUSINESS WIRE)--Maverick Medical AI Announces Completion of The Implementation of Its Real-Time Autonomous Medical Coding Solution at RadNet.
RadNet's Wholly-Owned Subsidiary, DeepHealth, to Use CARPL.ai's Platform to Develop a New AI Control System for Clinical AI Performance and Safety
LOS ANGELES and SOMERVILLE, Mass., Dec. 01, 2024 (GLOBE NEWSWIRE) -- DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly-owned subsidiary of RadNet, Inc. (NASDAQ: RDNT), today announced a strategic collaboration with CARPL.ai, a leading AI orchestration...
CORRECTION: RadNet's DeepHealth Subsidiary Expands FDA Clearance for SmartMammo™ Solution
SOMERVILLE, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Friday, November 29th by RadNet, Inc. (NASDAQ: RDNT), please note that in the third sentence of the first paragraph, the year that SmartMammo...
Source: https://incomestatements.info
Category: Stock Reports